| Sign In to gain access to subscriptions and/or personal tools. |
Effects of ipsapirone and cannabidiol on human experimental anxietyLaboratory of Psychobiology, FFCLRP, Campus USP, Ribeirao Preto, SP 14049, Brazil
Laboratory of Psychobiology, FFCLRP, Campus USP, Ribeirao Preto, SP 14049, Brazil
Laboratory of Psychobiology, FFCLRP, Campus USP, Ribeirao Preto, SP 14049, Brazil
Department of Neuropsychiatry and Pharmacology, Faculty of Medicine The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.
Key Words: cannabidiol diazepam ipsapirone anxiety public speaking
Journal of Psychopharmacology, Vol. 7, No. 1 suppl,
82-88 (1993) This article has been cited by other articles:
|
|||||||||||||||
